Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES (ABT)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Strengths
  • Its core activity has a significant growth potential and sales are expected to surge, according to Thomson Reuters' forecast. Indeed, those may increase by 53% by 2019.
  • The company returns high margins, thereby supporting business profitability.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The stock is in a well-established, long-term rising trend above the technical support level at 50.23 USD
Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • Technically, the stock approaches a strong medium-term resistance at USD 58.99.
  • The company's enterprise value to sales, at 4.4 times its current sales, is high.
  • With an expected P/E ratio at 50.72 and 38.89 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ABBOTT LABORATORIES3.10%102 417
JOHNSON & JOHNSON4.32%391 587
NOVARTIS1.80%225 838
ROCHE HOLDING LTD.-0.28%218 350
PFIZER0.88%217 804
MERCK AND COMPANY4.25%159 987
AMGEN6.41%134 322
SANOFI2.53%113 491
NOVO NORDISK A/S0.61%108 273
BAYER0.83%106 071
BRISTOL-MYERS SQUIBB COMPAN..2.50%102 801
ELI LILLY AND COMPANY2.98%95 773
GLAXOSMITHKLINE2.31%92 553
ASTRAZENECA0.21%89 569
CELGENE CORPORATION1.57%83 456
ALLERGAN PLC7.62%58 551
More Results
Financials ($)
Sales 2017 27 195 M
EBIT 2017 6 011 M
Net income 2017 2 227 M
Debt 2017 17 359 M
Yield 2017 1,82%
P/E ratio 2017 50,72
P/E ratio 2018 38,89
EV / Sales 2017 4,40x
EV / Sales 2018 3,88x
Capitalization 102 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ABBOTT LABORATORIES
Duration : Period : Day
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Duration : Period : Week
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders